Ablynx (BE) – ABLYNX WILL ANNOUNCE FULL YEAR RESULTS FOR 2009 WITH WEBCAST
ABLYNX WILL ANNOUNCE FULL YEAR RESULTS FOR 2009 WITH WEBCAST
GHENT, Belgium, 22 February 2010 – Ablynx [Euronext Brussels: ABLX] plans to announce its full year results for 2009 on 25 February 2009 after market closure.
Dr Edwin Moses, CEO and Chairman of Ablynx, will host a conference call webcast during which the full year results for 2009 will be presented, followed by a Q&A session. This event will be held on Friday, 26 February 2009 at 4.00 p.m. CET.
The conference call will be webcast live and can be accessed through the home page of the Ablynx website (www.ablynx.com).
About Ablynx [Euronext Brussels: ABLX] – http://www.ablynx.com
Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currently has over 230 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007.
Ablynx is developing a portfolio of Nanobody-based therapeutics in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer’s disease. Ablynx now has over 25 programmes in its therapeutic pipeline including four Nanobodies in clinical development. So far, Nanobodies have been successfully generated against more than 190 different protein targets including several complex targets such as chemokines, GPCRs, ion channels and viruses, which are typically very difficult to approach with conventional monoclonal antibodies. Efficacy data have been obtained in 28 in vivo models for Nanobodies against a range of different targets.
Ablynx has an extensive patent position in the field of Nanobodies for healthcare applications. It has exclusive and worldwide rights to more than 130 families of granted patents and pending patent applications, including the Hamers patents covering the basic structure, composition, preparation and uses of Nanobodies.
Ablynx has ongoing research collaborations and significant partnerships with several major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis and Pfizer (previously Wyeth Pharmaceuticals). Ablynx is building a diverse and broad portfolio of therapeutic Nanobodies through these collaborations as well as through its own internal discovery programmes.